Sanofi grap­ples with re­jec­tion of po­ten­tial first-in-class or­phan drug, faults third-par­ty man­u­fac­tur­ing

A snap re­view didn’t lead to a quick OK for Sanofi’s su­tim­limab. A day af­ter the FDA’s sup­posed de­ci­sion date on the or­phan drug, the French phar­ma gi­ant said it was hand­ed a re­jec­tion.

The com­plete re­sponse let­ter cites “cer­tain de­fi­cien­cies iden­ti­fied by the agency dur­ing a pre-li­cense in­spec­tion of a third-par­ty fa­cil­i­ty re­spon­si­ble for man­u­fac­tur­ing,” Sanofi wrote. Reg­u­la­tors ap­par­ent­ly didn’t take any is­sue with the clin­i­cal da­ta or safe­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA